Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...
Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...
Facilities Design Services supports the UTA community in planning, designing and implementing interior environments. As stewards of our campus’ building heritage, we bring both a long-range and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback